Aardvark Therapeutics, Inc. (AARD) Stock Forecast & Price Target

Compare

135 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AARD Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Aardvark

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AARD Stock 12 Month Forecast

Average Price Target

$32.67

▲(125.16% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Aardvark Therapeutics, Inc. in the last 3 months. The average price target is $32.67 with a high forecast of $50.00 and a low forecast of $18.00. The average price target represents a 125.16% change from the last price of $14.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,12.633846153846154,15.747692307692308,18.861538461538462,21.975384615384616,25.08923076923077,28.203076923076924,31.31692307692308,34.43076923076923,37.54461538461538,40.65846153846154,43.77230769230769,46.886153846153846,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,11.30076923076923,13.081538461538461,14.862307692307692,16.643076923076922,18.423846153846156,20.204615384615387,21.985384615384618,23.76615384615385,25.54692307692308,27.32769230769231,29.10846153846154,30.88923076923077,{"y":32.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.52,10.172307692307692,10.824615384615385,11.476923076923077,12.12923076923077,12.781538461538462,13.433846153846154,14.086153846153845,14.73846153846154,15.39076923076923,16.043076923076924,16.695384615384615,17.347692307692306,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$32.67

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leland Gershell

Oppenheimer

$35

Buy

141.21%

Upside

Initiated

12/23/25

Aardvark Therapeutics initiated with an Outperform at OppenheimerAardvark Therapeutics initiated with an Outperform at Oppenheimer

Tim Anderson

Bank of America Securities

$25

Buy

72.29%

Upside

Reiterated

12/18/25

Bank of America Securities Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)

Andy Hsieh

William Blair

Buy

―

Initiated

12/12/25

Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential

Ram Selvaraju

H.C. Wainwright

$40

Buy

175.67%

Upside

Reiterated

12/11/25

Aardvark Therapeutics' Promising Progress and Market Potential: Analyst Recommends Buy

Jeet Mukherjee

BTIG

$26

Buy

79.19%

Upside

Reiterated

12/11/25

Analysts' Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY)

Christopher Raymond

Raymond James

$47

Buy

223.91%

Upside

Initiated

12/02/25

Aardvark Therapeutics, Inc. (AARD) Gets a Buy from Raymond James

James Condulis

Stifel Nicolaus

$24

Buy

65.40%

Upside

Reiterated

11/14/25

Aardvark Therapeutics, Inc. (AARD) Receives a Buy from Stifel Nicolaus

Joshua Schimmer

Cantor Fitzgerald

$50

Buy

244.59%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)

Brian Abrahams

RBC Capital

$19→$18

Buy

24.05%

Upside

Reiterated

11/13/25

RBC Capital Sticks to Its Buy Rating for Aardvark Therapeutics, Inc. (AARD)

Michael Ulz

Morgan Stanley

$29

Buy

99.86%

Upside

Reiterated

11/04/25

Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments

Catherine Novack

JonesTrading

$33

Buy

127.43%

Upside

Initiated

09/30/25

Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leland Gershell

Oppenheimer

$35

Buy

141.21%

Upside

Initiated

12/23/25

Aardvark Therapeutics initiated with an Outperform at OppenheimerAardvark Therapeutics initiated with an Outperform at Oppenheimer

Tim Anderson

Bank of America Securities

$25

Buy

72.29%

Upside

Reiterated

12/18/25

Bank of America Securities Sticks to Their Buy Rating for Aardvark Therapeutics, Inc. (AARD)

Andy Hsieh

William Blair

Buy

―

Initiated

12/12/25

Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential

Ram Selvaraju

H.C. Wainwright

$40

Buy

175.67%

Upside

Reiterated

12/11/25

Aardvark Therapeutics' Promising Progress and Market Potential: Analyst Recommends Buy

Jeet Mukherjee

BTIG

$26

Buy

79.19%

Upside

Reiterated

12/11/25

Analysts' Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY)

Christopher Raymond

Raymond James

$47

Buy

223.91%

Upside

Initiated

12/02/25

Aardvark Therapeutics, Inc. (AARD) Gets a Buy from Raymond James

James Condulis

Stifel Nicolaus

$24

Buy

65.40%

Upside

Reiterated

11/14/25

Aardvark Therapeutics, Inc. (AARD) Receives a Buy from Stifel Nicolaus

Joshua Schimmer

Cantor Fitzgerald

$50

Buy

244.59%

Upside

Reiterated

11/13/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Aardvark Therapeutics, Inc. (AARD)

Brian Abrahams

RBC Capital

$19→$18

Buy

24.05%

Upside

Reiterated

11/13/25

RBC Capital Sticks to Its Buy Rating for Aardvark Therapeutics, Inc. (AARD)

Michael Ulz

Morgan Stanley

$29

Buy

99.86%

Upside

Reiterated

11/04/25

Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments

Catherine Novack

JonesTrading

$33

Buy

127.43%

Upside

Initiated

09/30/25

Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aardvark Therapeutics, Inc.

1 Month

xxx

Success Rate

3/4 ratings generated profit

Average Return

+9.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +9.00% per trade.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+18.62%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +18.62% per trade.

1 Year

Joshua SchimmerCantor Fitzgerald

Success Rate

4/4 ratings generated profit

Average Return

+47.52%

reiterated a buy rating 2 months ago

Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +47.52% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+47.52%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AARD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AARD has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AARD average Analyst price target in the past 3 months is 32.67.

Each month's total comprises the sum of three months' worth of ratings.

AARD Financial Forecast

AARD Earnings Forecast

Next quarter’s earnings estimate for AARD is -$0.84 with a range of -$1.00 to -$0.70. The previous quarter’s EPS was -$0.75. AARD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AARD has Performed in-line its overall industry.

No data currently available

AARD Sales Forecast

Next quarter’s sales forecast for AARD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AARD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AARD has Performed in-line its overall industry.

AARD Stock Forecast FAQ

What is AARD’s average 12-month price target, according to analysts?

Based on analyst ratings, Aardvark Therapeutics, Inc.’s 12-month average price target is 32.67.

What is AARD’s upside potential, based on the analysts’ average price target?

Aardvark Therapeutics, Inc. has 125.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AARD a Buy, Sell or Hold?

Aardvark Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Aardvark Therapeutics, Inc.’s price target?

The average price target for Aardvark Therapeutics, Inc. is 32.67. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 125.16% Increase from the current price of $14.51.

What do analysts say about Aardvark Therapeutics, Inc.?

Aardvark Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of AARD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Aardvark Therapeutics, Inc. (AARD) Stock Forecast & Price Target

AARD Analyst Ratings

AARD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aardvark Therapeutics, Inc.

AARD Analyst Recommendation Trends

AARD Financial Forecast

AARD Earnings Forecast

AARD Sales Forecast

AARD Stock Forecast FAQ

Detailed List of Analyst Forecasts